In a retrospective, single-center study of 84 pediatric CF patients, Levitte et al. observed significant reductions in liver enzymes, including gamma-glutamyl transferase, and in biomarkers of hepatic fibrosis, such as the aspartate aminotransferase-to-platelet ratio index and the gamma-glutamyl transferase-to-platelet ratio, among patients with liver involvement who were treated with dual CFTR modulator, ivacaftor-lumacaftor.18 This evidence concerns the gene CFTR and Hepatic fibrosis.